What is HC Wainwright’s Estimate for Altimmune Q1 Earnings?

Altimmune, Inc. (NASDAQ:ALT) – HC Wainwright increased their Q1 2026 earnings per share (EPS) estimates for Altimmune in a report released on Monday, March 16th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings of ($0.23) per share for the quarter, up from their previous forecast of ($0.27). HC Wainwright currently has a “Buy” rating and a $25.00 price target on the stock. The consensus estimate for Altimmune’s current full-year earnings is ($1.35) per share. HC Wainwright also issued estimates for Altimmune’s Q2 2026 earnings at ($0.24) EPS, Q3 2026 earnings at ($0.25) EPS, Q4 2026 earnings at ($0.25) EPS, FY2026 earnings at ($0.97) EPS, Q1 2027 earnings at ($0.28) EPS, Q2 2027 earnings at ($0.30) EPS, Q3 2027 earnings at ($0.32) EPS, FY2027 earnings at ($1.20) EPS, FY2028 earnings at ($1.19) EPS, FY2029 earnings at ($0.79) EPS and FY2030 earnings at ($0.56) EPS.

Altimmune (NASDAQ:ALT) last issued its earnings results on Thursday, March 5th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.02). The business had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.00 million. Altimmune had a negative return on equity of 49.35% and a negative net margin of 214,860.98%.

A number of other research firms also recently issued reports on ALT. Weiss Ratings reiterated a “sell (d-)” rating on shares of Altimmune in a research note on Monday, December 29th. B. Riley Financial reduced their price objective on shares of Altimmune from $18.00 to $13.00 and set a “buy” rating for the company in a research note on Friday, March 6th. William Blair restated a “market perform” rating on shares of Altimmune in a report on Thursday, March 5th. Wall Street Zen cut Altimmune from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. Finally, Barclays started coverage on Altimmune in a report on Tuesday, January 27th. They issued an “overweight” rating and a $20.00 price target on the stock. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $18.00.

Altimmune Trading Down 3.1%

NASDAQ:ALT opened at $3.42 on Wednesday. The firm has a 50-day simple moving average of $4.46 and a 200-day simple moving average of $4.29. Altimmune has a one year low of $2.90 and a one year high of $7.73. The firm has a market cap of $444.84 million, a P/E ratio of -3.39 and a beta of 0.13. The company has a debt-to-equity ratio of 0.15, a quick ratio of 18.55 and a current ratio of 18.55.

Insider Buying and Selling

In other news, CEO Jerome Benedict Durso bought 20,000 shares of the stock in a transaction on Friday, March 6th. The stock was bought at an average cost of $3.54 per share, for a total transaction of $70,800.00. Following the completion of the purchase, the chief executive officer directly owned 32,500 shares in the company, valued at approximately $115,050. The trade was a 160.00% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director John Gill purchased 12,500 shares of the business’s stock in a transaction on Tuesday, December 23rd. The stock was purchased at an average cost of $4.10 per share, for a total transaction of $51,250.00. Following the completion of the acquisition, the director directly owned 12,500 shares of the company’s stock, valued at approximately $51,250. The trade was a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders bought 55,527 shares of company stock worth $213,778. Insiders own 4.40% of the company’s stock.

Institutional Trading of Altimmune

A number of institutional investors have recently made changes to their positions in the business. Geode Capital Management LLC raised its stake in Altimmune by 13.4% in the second quarter. Geode Capital Management LLC now owns 1,934,880 shares of the company’s stock valued at $7,489,000 after buying an additional 228,995 shares during the last quarter. Brown Wealth Management LLC boosted its holdings in Altimmune by 131.0% in the second quarter. Brown Wealth Management LLC now owns 231,083 shares of the company’s stock worth $894,000 after acquiring an additional 131,059 shares in the last quarter. Intech Investment Management LLC grew its stake in shares of Altimmune by 102.9% during the second quarter. Intech Investment Management LLC now owns 144,890 shares of the company’s stock worth $561,000 after acquiring an additional 73,482 shares during the last quarter. Jefferies Financial Group Inc. increased its holdings in shares of Altimmune by 40.0% during the second quarter. Jefferies Financial Group Inc. now owns 35,000 shares of the company’s stock valued at $135,000 after acquiring an additional 10,000 shares in the last quarter. Finally, Steward Partners Investment Advisory LLC increased its holdings in shares of Altimmune by 43.0% during the second quarter. Steward Partners Investment Advisory LLC now owns 213,384 shares of the company’s stock valued at $826,000 after acquiring an additional 64,175 shares in the last quarter. Institutional investors and hedge funds own 78.05% of the company’s stock.

More Altimmune News

Here are the key news stories impacting Altimmune this week:

• Positive Sentiment: Truist initiated coverage with a “Buy” and a $12.00 price target (roughly 250% upside vs. current levels), which could attract buyers and improve sentiment. Read More.
• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and a $25 price target and raised several near‑term EPS forecasts (Q1–Q4 2026 and FY2026/FY2027 upgrades and smaller quarter‑by‑quarter EPS improvements), signaling improved near‑term operating expectations. Read More.
• Neutral Sentiment: Reported short‑interest entries show a large “increase” but list 0 shares and NaN changes, with days‑to‑cover = 0.0 — this appears to be a data glitch and unlikely to have a clear market effect unless corrected. (No external link available)
• Negative Sentiment: HC Wainwright also trimmed longer‑term forecasts materially (FY2028 and FY2029 EPS were reduced), indicating weaker expected longer‑term profitability; this could limit enthusiasm for the very high $25 PT or lead some investors to remain cautious. Read More.

About Altimmune

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.